FTC Disclosure:
Heads up — these are partners that pay us a commission if you sign up. Our editorial picks are independent. Educational content — not medical advice. Talk to your licensed physician before starting any medication. See our full disclosure.
Tirzepatide in the US 2026: real prices + honest alternatives
A grounded comparison of tirzepatide pricing in the United States: brand (Zepbound, Mounjaro), Eli Lilly direct cash-pay, and compounded tirzepatide via the regulated telehealth platforms we review.
Educational only. Not medical advice. Talk to your licensed physician before starting, changing, or stopping any GLP-1 medication. This page does not diagnose or treat any condition.
1. What tirzepatide is (and how it compares to semaglutide)
Tirzepatide is a dual receptor agonist: it activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. Semaglutide, by contrast, activates only GLP-1. The dual mechanism is what produces tirzepatide's larger mean weight loss in head-to-head data — but the side effect profile is similar, and individual response varies.
Tirzepatide is manufactured by Eli Lilly under two brand names: Zepbound (FDA-approved for chronic weight management in adults with obesity or overweight with at least one weight-related condition) and Mounjaro (FDA-approved for type 2 diabetes). Both are the same active molecule; the indication and dosing differ.
Head-to-head clinical evidence:
SURMOUNT-1 (Jastreboff et al., NEJM 2022, PMID 35658024): 22.5% mean weight loss over 72 weeks with tirzepatide 15mg.
STEP-1 (Wilding et al., NEJM 2021, PMID 33567185): 14.9% mean weight loss over 68 weeks with semaglutide 2.4mg.
SURMOUNT-5 (2024): tirzepatide vs semaglutide head-to-head — tirzepatide produced greater mean weight loss in adults with obesity without diabetes.
Choosing between them is not a clear-cut "tirzepatide is always better" call. Cost, availability, dosing tolerance, and personal side-effect response all matter. Many users start on compounded semaglutide for cost reasons and switch to tirzepatide later if response plateaus.
2. Official pricing: Zepbound + Mounjaro 2026
Zepbound (tirzepatide for weight loss): Eli Lilly's published list price for Zepbound autoinjector pens is approximately $1,060-$1,300/month depending on dose, before any insurance, coupons, or manufacturer programs. Most major commercial insurance plans cover Zepbound only when BMI and clinical criteria are met (typically BMI ≥30, or ≥27 with weight-related comorbidity). Medicare has covered Zepbound's sibling Wegovy since 2025 for cardiovascular risk; Zepbound Medicare coverage continues to expand in 2026.
Mounjaro (tirzepatide for type 2 diabetes): List price runs roughly $1,000-$1,200/month at retail. Coverage is broader than Zepbound because diabetes is a more universally covered indication. Most commercial plans cover Mounjaro with a copay typically between $25-$100/month for patients who qualify.
The list price is not what most insured patients pay. Manufacturer savings cards (LillyDirect, Mounjaro Savings Card, Zepbound Savings Card) can substantially reduce the cash cost for eligible commercially insured patients. Uninsured patients pay close to list price at retail — which is what drives many toward compounded alternatives or Eli Lilly's direct cash-pay channel.
3. Eli Lilly direct cash-pay program
In 2024 Eli Lilly launched LillyDirect, a direct-to-consumer channel that sells Zepbound single-dose vials at meaningfully reduced cash-pay pricing. The vials require self-injection with a separately purchased syringe rather than the more convenient autoinjector pen — a small trade-off for the price reduction.
Key facts about LillyDirect (verify current details at lilly.com/zepbound-direct):
Cash-pay only — does not run through insurance.
Vials sold per dose strength (2.5mg, 5mg, 7.5mg, 10mg) with discounted pricing per vial.
Requires a prescription from a licensed clinician (telehealth or in-person).
Ships refrigerated to your home.
Available for Zepbound (tirzepatide for weight loss), not currently for Mounjaro.
For uninsured patients who want branded tirzepatide and don't want to deal with compounded products, LillyDirect is the most economical path. Pricing is still typically higher than most compounded tirzepatide via telehealth, but you get FDA-approved branded product with full traceability.
4. Compounded tirzepatide — post-503B Bulks List status
The FDA declared the tirzepatide shortage resolved in early 2025. That single decision narrowed — but did not eliminate — the legal pathway for compounded tirzepatide.
Legal compounding routes that remain open in 2026:
503A patient-specific compounding with documented clinical personalization — dose adjustments outside the standard menu (e.g., 4mg, 6mg, 8mg intermediate doses not commercially available), allergen exclusion (B12-free formulations), or combination formulations (e.g., tirzepatide + B6 for nausea management).
503B outsourcing facilities — these can produce tirzepatide if the active ingredient appears on the FDA's 503B Bulks List or if a clear clinical need is documented. The 503B Bulks List status of tirzepatide is the most important regulatory variable to watch in 2026.
Documented clinical need cases — supply gaps in specific dose strengths or in specific geographies can support continued compounding.
In March 2026 the FDA sent warning letters to roughly 30 telehealth companies about compounded GLP-1 marketing. Those letters targeted advertising language (claims that compounded versions are equivalent to FDA-approved branded product, off-label dose promotions), not the underlying legality of compounding itself. Read the full legal deep-dive: /compounded-glp1-2026-legal.html.
For uninsured patients, compounded tirzepatide via regulated telehealth ($249-$400/month) is currently the most economical legal route. Always verify the provider discloses their partner pharmacy and requires a documented medical consultation before shipping.
5. 9 telehealth platforms with tirzepatide — pricing table + top 3 picks
Pricing reflects tirzepatide-specific protocols where offered. Some providers only carry compounded semaglutide; those are marked. Verify current rates on each provider's site.
SkinnyRx — compounded tirzepatide from $249/month, Affirm financing
SkinnyRx is the lowest entry point for compounded tirzepatide among the providers we review. Multiple formulations (injectable, sublingual, oral) and Affirm financing make it the practical pick for buyers on tight monthly budgets. Important context: SkinnyRx received an FDA warning letter in early 2026 about marketing language (not product safety). We cover that in the full review.
Heads up — these are partners that pay us a commission if you sign up. Our editorial picks are independent.
GobyMeds — flexible compounded tirzepatide dosing, cleanest FDA record
GobyMeds offers the most flexible compounded tirzepatide dose menu in the set we review, including intermediate doses (4mg, 6mg, 8mg) not commercially available in branded Zepbound. For users who plateau on standard escalation or need fine-grained titration to manage side effects, that flexibility is the differentiator. GobyMeds also has the cleanest FDA standing of any compounded provider in our set as of May 2026.
Heads up — these are partners that pay us a commission if you sign up. Our editorial picks are independent.
Yucca Health — established brand, Trustpilot 4.6, 503A pharmacy disclosed
Yucca Health remains the most regulator-conservative compounded tirzepatide provider we review: Trustpilot 4.6 with thousands of verified reviews, open disclosure of the partner 503A pharmacy that prepares the compound, and zero FDA warning letters to date. For buyers who want the strongest paper trail from a compliance perspective, Yucca is the pick. Pricing varies by selected protocol.
Heads up — these are partners that pay us a commission if you sign up. Our editorial picks are independent.
How much does tirzepatide cost in the United States in 2026?
Without insurance, brand tirzepatide (Zepbound for weight loss, Mounjaro for type 2 diabetes) runs roughly $1,000-$1,300/month at retail. The Eli Lilly Direct program offers Zepbound vials at reduced cash-pay pricing (check the current rate at lilly.com/zepbound-direct). Compounded tirzepatide through regulated telehealth runs $249-$400/month depending on the provider.
Is compounded tirzepatide legal in 2026 after the shortage ended?
Yes, under specific conditions. The FDA declared the tirzepatide shortage resolved in early 2025, which narrowed the compounding pathway. However, 503A pharmacies can still compound tirzepatide under clinical personalization exemptions (dose adjustments, allergen exclusions, combination formulations with B6 or B12). 503B outsourcing facilities can produce it if the active ingredient appears on the 503B Bulks List or if documented clinical need exists. Telehealth providers still offering compounded tirzepatide operate under these frameworks.
What is the difference between semaglutide and tirzepatide?
Semaglutide is a single GLP-1 receptor agonist. Tirzepatide is a dual agonist: it acts on GLP-1 and also on GIP (glucose-dependent insulinotropic polypeptide). In head-to-head clinical studies, tirzepatide produced greater mean weight loss (22.5% in SURMOUNT-1 at 72 weeks with 15mg) versus semaglutide (14.9% in STEP-1 at 68 weeks with 2.4mg). Side effect profiles are similar; the choice often comes down to cost, availability, and individual response.
Does the Eli Lilly Direct program sell tirzepatide more cheaply?
Eli Lilly launched the Lilly Direct program with Zepbound vials at reduced cash-pay pricing (bypassing insurance). The vials require self-injection with a separate syringe rather than an autoinjector pen. Pricing is meaningfully lower than retail brand pricing for some doses, but still higher than most compounded tirzepatide via telehealth. Check current pricing and availability at lilly.com/zepbound-direct.
Which telehealth provider offers tirzepatide with bilingual support in 2026?
Among the providers we review, SkinnyRx, GobyMeds, Yucca Health, and System Labs offer compounded tirzepatide. All handle the main intake form in English with messaging support that can be answered in Spanish. Full Spanish medical consultation requires asking specifically for a "Spanish-speaking provider" when enrolling. A handful of local clinics in Florida, Texas, and California offer 100% Spanish consultation but may have different pricing structures.
Editorial independence
The platforms listed are affiliate partners. Our affiliate compensation does not change the ranking order — we recommend SkinnyRx, GobyMeds, and Yucca Health for compounded tirzepatide because they combine accessible pricing, dosing flexibility, and verifiable legal operation, not because they pay higher commissions. Read the full disclosure.
References: SURMOUNT-1 (Jastreboff et al., NEJM 2022, PMID 35658024) for tirzepatide efficacy. STEP-1 (Wilding et al., NEJM 2021, PMID 33567185) for semaglutide efficacy. FDA Drug Shortages Database for tirzepatide shortage resolution status. FDA 503B Bulks List for compounding framework. Eli Lilly LillyDirect for direct cash-pay pricing.